Back to Search
Start Over
Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia.
Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia.
- Source :
-
Haematologia [Haematologia (Budap)] 2002; Vol. 32 (2), pp. 169-73. - Publication Year :
- 2002
-
Abstract
- We present the case of a 71 year-old man with secondary acute myeloblastic leukemia, who was successfully treated with low dose melphalan plus Epo plus G-CSF. We treated the patient with 2 mg of melphalan once a day orally, G-CSF 5 mg/kg 3 times a week and Epo 10.000 ui subcutaneously 3 times a week until the maximum response was obtained. Complete remission was achieved after 16 weeks of continuous treatment. Treatment-related toxicity was not significant. We recommend the use of low dose melphalan in elderly patients with high risk MDS as a treatment option.
- Subjects :
- Aged
Anemia, Refractory, with Excess of Blasts drug therapy
Drug Therapy, Combination
Erythropoietin administration & dosage
Granulocyte Colony-Stimulating Factor administration & dosage
Humans
Leukemia, Myeloid, Acute complications
Male
Myelodysplastic Syndromes complications
Remission Induction
Risk Assessment
Leukemia, Myeloid, Acute drug therapy
Melphalan administration & dosage
Myelodysplastic Syndromes drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0017-6559
- Volume :
- 32
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Haematologia
- Publication Type :
- Academic Journal
- Accession number :
- 12412738
- Full Text :
- https://doi.org/10.1163/156855902320388023